The official Drugs@FDA dataset lists original submission 1 for NDA 203441 with status AP dated 2012-12-21, and names teduglutide among the application record's active ingredients.
The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients.
The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.
The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.
The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
DailyMed lists Structured Product Labeling version 2 for the reviewed Linaclotide label family with a published date of 2012-09-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The official Drugs@FDA dataset lists original submission 1 for NDA 202811 with status AP dated 2012-08-30, and names linaclotide among the application record's active ingredients.
The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.
The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.
The Federal Register published notice 2012-12040, attributed to FDA and its parent HHS department, on 2012-05-18. Its official title is “Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.
The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
The official Drugs@FDA dataset lists original submission 1 for ANDA 077212 with status AP dated 2012-04-12, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.
The Federal Register published notice 2012-6971, attributed to FDA and its parent HHS department, on 2012-03-23. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Secretin.
The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients.
The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.